Clinical trials: Disorder of Circulatory System
Type 2 Diabetes Mellitus, Coronary Artery Disease
Aspirin Dosing in Diabetic Patients
Since diabetic platelets are characterized by an enhanced turnover rate, it may be hypothesized that an increase in the frequency, rather than the dose, of drug administration may be a more effective strategy to inhibit platelet…
- Trial name
- NCT01201785
- Testing
- Aspirin
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Florida
Acute Coronary Syndrome, TIA
Early Psychological Intervention to Prevent Cardiovascular Event-Induced PTSD (REACH Sub-study)
The overall purpose of this project is to determine the feasibility of conducting a randomized clinical trial that compares written exposure therapy with usual care among patients at risk for cardiovascular event-induced PTSD.
- Conditions
- Acute Coronary Syndrome, TIA, Stroke, Cardiac Arrest
- Trial name
- NCT03605693
- Testing
- Written Exposure Therapy
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Columbia University
Relapsed Refractory Multiple Myeloma
Study to Evaluate Safety Tolerability & Efficacy of Kyprolis (Carfilzomib) in Relapsed or Refractory Multiple Myeloma
To characterize safety associated with the use of Kyprolis under the locally approved label.
- Trial name
- NCT03934684
- Testing
- Drug: Carfilzomib + Dexamethasone, Drug: Carfilzomib + Lenalidomide + Dexamethasone
- Where
- 17 sites in India
- Volunteers
- 101 people
- Sponsor
- Amgen
Acute Ischemic Stroke
Safety and Efficacy of Intravenous Natalizumab in Acute Ischemic Stroke
The primary objective of the study is to assess the clinical effects of natalizumab versus placebo in acute ischemic stroke on clinical measures of functional independence and activities of daily living.
- Trial name
- ACTION2 (NCT02730455)
- Testing
- natalizumab
- Where
- 53 sites in United States, Germany and 2 more
- Volunteers
- 277 people
- Sponsor
- Biogen
Chronic Myeloproliferative Disorders, Leukemia
Fludarabine, Cyclophosphamide, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer
RATIONALE: Giving low doses of chemotherapy, such as fludarabine and cyclophosphamide, and radiation therapy before a donor bone marrow transplant helps stop the growth of cancer cells.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00134004
- Testing
- cyclophosphamide, fludarabine phosphate, mycophenolate mofetil
- Where
- 3 sites in United States
- Volunteers
- 210 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
ANCA-associated Vasculitis
Clinical Trial to Evaluate Safety and Efficacy of CCX168 in ANCA-Associated Vasculitis
The aim of this trial is to test the safety and efficacy of two dose regimens of the complement C5a receptor CCX168 in patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV).
- Trial name
- NCT02222155
- Testing
- CCX168 10 mg, twice daily, plus cyclophosphamide/rituximab plus glucocorticoids, CCX168 30 mg, twice daily, cyclophosphamide/rituximab plus glucocorticoids
- Where
- 43 sites in United States, Canada
- Volunteers
- 42 people
- Sponsor
- Amgen
Non-infectious Uveitis
Safety and Efficacy of AIN457 in Noninfectious Uveitis
This study was performed to evaluate the efficacy and safety of AIN457 for patients with active uveitis that requires systemic immunosuppression.
- Trial name
- NCT00685399
- Testing
- AIN457, AIN 457
- Where
- 23 sites in United States, Germany
- Volunteers
- 76 people
- Sponsor
- Novartis Pharmaceuticals
Cerebrovascular Disease
The Neuroprotective Effect of Remote Ischemic Preconditioning on Ischemic Cerebral Vascular Disease
This study is a prospective, randomized, single-center trial, designed to observe the effect of remote limb ischemic preconditioning on ischemic cerebral vascular disease.
- Trial name
- NCT01321749
- Testing
- Remote ischemic preconditioning (RIPC)
- Where
- China
- Volunteers
- 196 people
- Sponsor
- Capital Medical University
Brain Neoplasms, Surgery
Cerebral Blood Perfusion Changes After General Anesthesia for Craniotomy
Few studies look into cerebral blood flow (CBF) changes during emergence from general anesthesia for craniotomy. The purpose of this study is to demonstrate CBF changes during emergence from general anesthesia for craniotomy…
- Conditions
- Brain Neoplasms, Surgery, Hyperemia
- Trial name
- NCT01642147
- Testing
- Transcranial Doppler (TCD), jugular venous bulb catheterization, Tumor removal surgery under general anesthesia
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Huashan Hospital
Corneal Epithelial Defect, Diabetic Retinopathy
Topical Autologous Serum Application for the Treatment of Corneal Epithelium Defect After Ocular Surgeries
Ophthalmology ,cornea Autologous serum has long been known to be effective to promote corneal epithelial wound healing in a variety of ocular surface disorders.
- Conditions
- Corneal Epithelial Defect, Diabetic Retinopathy, Penetrating Keratoplasty
- Trial name
- NCT01075347
- Testing
- autologous serum, Non-autologous serum
- Where
- Taiwan
- Volunteers
- 165 people, healthy volunteers welcome
- Sponsor
- National Taiwan University Hospital
Paroxysmal Atrial Fibrillation
A Safety and Feasibility Study of the FARAPULSE Endocardial Ablation System to Treat Paroxysmal Atrial Fibrillation
PEFCAT is a prospective, single-arm, multi-center, safety and feasibility study evaluating the FARAPULSE Endocardial Ablation System for the treatment of paroxysmal atrial fibrillation.
- Trial name
- NCT03714178
- Testing
- FARAPULSE Endocardial Ablation System
- Where
- 2 sites in Czechia, France
- Volunteers
- 71 people
- Sponsor
- Boston Scientific Corporation
Multiple Myeloma
Carfilzomib, Clarithromycin (Biaxin®), Lenalidomide (Revlimid®), and Dexamethasone (Decadron®) [Car-BiRD] Therapy for Subjects With Multiple Myeloma
The purpose of this study is to evaluate the safety and effectiveness of an investigational new drug called carfilzomib, in combination with dexamethasone in subjects with newly diagnosed multiple myeloma followed by treatment…
- Trial name
- CarBiRD (NCT01559935)
- Testing
- carfilzomib, Dexamethasone, Clarithromycin
- Where
- United States
- Volunteers
- 74 people
- Sponsor
- Weill Medical College of Cornell University
Diabetes Mellitus, Type 2
BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME).
The aim of the present study is to investigate the safety of BI 10773 treatment in patients with Type 2 Diabetes Mellitus and high cardiovascular risk.
- Trial name
- NCT01131676
- Testing
- BI 10773 low dose, BI 10773 high dose
- Where
- 615 sites in United States, Argentina and 40 more
- Volunteers
- 7,064 people
- Sponsor
- Boehringer Ingelheim
Heart Failure, Sleep Disordered Breathing
Treatment of Predominant Central Sleep Apnoea by Adaptive Servo Ventilation in Patients With Heart Failure
The purpose of this trial is to evaluate the long-term effects and cost-effectiveness of adaptive servo-ventilation (ASV) on the mortality and morbidity of patients with stable heart failure due to left ventricular systolic…
- Trial name
- Serve-HF (NCT00733343)
- Testing
- Europe: AutoSet CS (USA: VPAP Adapt SV)
- Where
- 267 sites in Australia, Czechia and 9 more
- Volunteers
- 1,325 people
- Sponsor
- ResMed
Refractory Multiple Myeloma, Multiple Myeloma in Relapse
Study of Ibrutinib in Combination With Revlimid/Dexamethasone in Relapsed/Refractory Multiple Myeloma
This is a registration, open-label phase 1 study of the combination of ibrutinib/lenalidomide:/dexamethasone in women and men with relapsed/refractory multiple myeloma.
- Conditions
- Refractory Multiple Myeloma, Multiple Myeloma in Relapse, Multiple Myeloma
- Trial name
- NCT03702725
- Testing
- Ibrutinib, Lenalidomide, Dexamethasone
- Where
- 5 sites in United States
- Volunteers
- 14 people
- Sponsor
- Alliance Foundation Trials, LLC.
Peripheral Vascular Disease, Embolism and Thrombosis
Registry of AngioJet Use in the Peripheral Vascular System
The Registry involves the collection of information for research and educational purposes only on the use of AngioJet in the peripheral vascular system.
- Conditions
- Peripheral Vascular Disease, Embolism and Thrombosis, Venous Thrombosis
- Trial name
- PEARLII (NCT01086215)
- Where
- 36 sites in United States, Canada and 3 more
- Volunteers
- 500 people
- Sponsor
- Boston Scientific Corporation
Multiple Myeloma
Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Clinical Activity of GSK2857916
This study will assess the safety, pharmacokinetic (PK), pharmacodynamic (PD) and the therapeutic potential of GSK2857916 in subjects with multiple myeloma (MM) and lymphomas that express B cell maturation antigen (BCMA).
- Trial name
- NCT02064387
- Testing
- GSK2857916
- Where
- 9 sites in United States, Canada and 1 more
- Volunteers
- 79 people
- Sponsor
- GlaxoSmithKline
Hereditary Angioedema, Angioneurotic Edema
Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema
Hereditary angioedema ("HAE") is a genetic disorder characterized by sudden recurrent attacks of local swelling (angioedema). These attacks are often painful and disabling, and, in some cases, life-threatening.
- Trial name
- NCT00225147
- Testing
- Recombinant Human C1 Inhibitor
- Where
- Netherlands
- Volunteers
- 77 people
- Sponsor
- Pharming Technologies B.V.
Cancer
Aprepitant in Preventing Nausea and Vomiting in Patients Who Are Undergoing a Stem Cell Transplant
RATIONALE: Antiemetic drugs, such as aprepitant, ondansetron, and dexamethasone, may help lessen or prevent nausea and vomiting in patients undergoing a stem cell transplant.
- Trial name
- NCT00248547
- Testing
- aprepitant, dexamethasone, ondansetron
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- OHSU Knight Cancer Institute
Diabetic Kidney Disease
Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease
The purpose of this study was to evaluate whether oral finerenone (study drug), in addition to standard daily therapy, is effective and safe in treating patients with type 2 diabetes mellitus and diabetic kidney disease, when…
- Trial name
- FIGARO-DKD (NCT02545049)
- Testing
- Finerenone (BAY94-8862)
- Where
- 975 sites in United States, Argentina and 46 more
- Volunteers
- 7,352 people
- Sponsor
- Bayer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.